← Back to Search

Protease Inhibitor

Nirmatrelvir/Ritonavir for COVID-19 in Children

Phase 2 & 3
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and female, age 0 to < 18 years, able to swallow
Male and female, age 0 to < 18 years, able to swallow for some participants
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1: 1 hour-post dose; day 2: 2-8 hours post dose; day 3: 2-8 hours post dose; day 4: 2-8 hours post dose; day 5: pk pre-dose and post-dose 1 to 3 hours
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective in treating kids with COVID-19 who are not hospitalized.

Who is the study for?
This trial is for children and teenagers under 18 who can swallow pills, have tested positive for COVID-19 within the last 72 hours, are at risk of severe illness but not hospitalized. They must show symptoms within 5 days before joining. Those with certain treatments or conditions like severe kidney issues, other infections, or using specific drugs that affect the body's drug processing system cannot join.Check my eligibility
What is being tested?
The study tests PF-07321332 (Nirmatrelvir)/Ritonavir in young patients to see how safe it is and how well it works against COVID-19. It looks at how their bodies handle the medication and its effectiveness in preventing serious disease.See study design
What are the potential side effects?
While specific side effects for this age group aren't listed here, Nirmatrelvir/Ritonavir may cause gastrointestinal issues like diarrhea, taste disturbances, high blood pressure, muscle aches, and allergic reactions in adults.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are able to swallow.
Select...
You started showing signs of COVID-19 within 5 days before joining the study, and you still have at least one of the specific COVID-19 signs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1: 1 hour-post dose; day 2: 2-8 hours post dose; day 3: 2-8 hours post dose; day 4: 2-8 hours post dose; day 5: pk pre-dose and post-dose 1 to 3 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1: 1 hour-post dose; day 2: 2-8 hours post dose; day 3: 2-8 hours post dose; day 4: 2-8 hours post dose; day 5: pk pre-dose and post-dose 1 to 3 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cohort 1-2: Area Under the Curve to the End of the Dosing Period (AUC0-tau) of nirmatrelvir and ritonavir
Cohort 1-2: Maximum Observed Plasma Concentration (Cmax) of nirmatrelvir and ritonavir
Cohort 3: Area Under the Curve to the End of the Dosing Period (AUC0-tau) of nirmatrelvir and ritonavir
+7 more
Secondary outcome measures
Patient assessment on acceptability and palatability of nirmatrelvir/ritonavir (film-coated tablets and oral powder)
Proportion of participants with COVID-19 related hospitalization or death from any cause
Viral load assessment titers measured via reverse transcription polymerase chain reaction (RT-PCR) in nasopharyngeal or nasal swabs over time

Side effects data

From 2012 Phase 4 trial • 68 Patients • NCT00757783
32%
Diarrhoea
26%
Nausea
16%
Cough
13%
Low Density Lipoprotein Increased
13%
Fatigue
13%
Pyrexia
10%
Abdominal Distension
10%
Immune Reconstitution Syndrome
6%
Weight Decreased
6%
Flatulence
6%
Tinea Pedis
6%
Upper Respiratory Tract Infection
6%
Decreased Appetite
6%
Penile Discharge
6%
Sinus Congestion
6%
Acne
6%
Pain
6%
Influenza
6%
Neutropenia
6%
Headache
6%
Rash
3%
Abdominal Pain
3%
Blood Cholesterol Increased
3%
Dyspepsia
3%
Urinary Tract Infection
3%
Dizziness
3%
Depression
3%
Insomnia
3%
Oral Herpes
3%
Pain in Extremity
3%
Pancreatitis
3%
Muscle Strain
3%
Blood Glucose Increased
3%
Diabetes Mellitus
3%
Chronic Obstructive Pulmonary Disease
3%
Respiratory Distress
100%
80%
60%
40%
20%
0%
Study treatment Arm
Darunavir
Atazanavir

Trial Design

5Treatment groups
Experimental Treatment
Group I: Cohort 5 nirmatrelvir/ritonavirExperimental Treatment2 Interventions
nirmatrelvir/ritonavir <1 month (<28 days) old
Group II: Cohort 4 nirmatrelvir/ritonavirExperimental Treatment2 Interventions
nirmatrelvir/ritonavir ≥1 month (≥28 days) to <2 years
Group III: Cohort 3 nirmatrelvir/ritonavirExperimental Treatment2 Interventions
nirmatrelvir/ritonavir ≥2 to <6 years
Group IV: Cohort 2 nirmatrelvir/ritonavirExperimental Treatment2 Interventions
nirmatrelvir/ritonavir will be given as powder by mouth twice a day for 5 days (10 doses total) Weight ≥20 to <40 kg, ≥6 to <18 years
Group V: Cohort 1 nirmatrelvir/ritonavirExperimental Treatment2 Interventions
nirmatrelvir/ritonavir will be given by tablets or powder by mouth twice a day for 5 days (10 doses total). Weight ≥40 kg ≥12 to <18 years ≥6 to <12 years
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ritonavir
2011
Completed Phase 4
~2000
nirmatrelvir
2022
Completed Phase 2
~440

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,565 Previous Clinical Trials
10,907,077 Total Patients Enrolled
67 Trials studying COVID-19
1,438,493 Patients Enrolled for COVID-19
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,472 Previous Clinical Trials
8,088,245 Total Patients Enrolled
49 Trials studying COVID-19
1,427,270 Patients Enrolled for COVID-19

Media Library

Nirmatrelvir (Protease Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05261139 — Phase 2 & 3
COVID-19 Research Study Groups: Cohort 2 nirmatrelvir/ritonavir, Cohort 5 nirmatrelvir/ritonavir, Cohort 3 nirmatrelvir/ritonavir, Cohort 4 nirmatrelvir/ritonavir, Cohort 1 nirmatrelvir/ritonavir
COVID-19 Clinical Trial 2023: Nirmatrelvir Highlights & Side Effects. Trial Name: NCT05261139 — Phase 2 & 3
Nirmatrelvir (Protease Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05261139 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many medical centers are coordinating this research project?

"At the moment, there are 70 medical centres running this clinical trial. If you are interested in participating, know that some of the locations include Houston, Minneapolis and Parma. Additionally, selecting the site nearest to your home can help reduce travel-related burdens."

Answered by AI

Who does this clinical trial hope to include in its sample size for research?

"Eligible participants for this coronavirus trial must be infected with SARS-CoV-2 and between the ages of 0 to 17. This research is looking to have around 140 patients enrolled."

Answered by AI

Does the age restriction for this clinical trial end at 70 years old?

"The target patient demographic for this clinical trial are those that have not yet reached their 18th birthday."

Answered by AI

Who else is applying?

What state do they live in?
Georgia
Virginia
Alabama
How old are they?
18 - 65
< 18
What site did they apply to?
Life Spring Research Foundation
Coastal Pediatric Research
Children's National Medical Center
Other
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. Coastal Pediatric Research: < 48 hours
Average response time
  • < 2 Days
~97 spots leftby Jul 2027